A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
Abstract Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to it...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7ea57068e99f4b3d9f9d8844f0926591 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7ea57068e99f4b3d9f9d8844f0926591 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7ea57068e99f4b3d9f9d8844f09265912021-12-02T15:10:24ZA pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs10.1038/s41598-020-75533-42045-2322https://doaj.org/article/7ea57068e99f4b3d9f9d8844f09265912020-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-75533-4https://doaj.org/toc/2045-2322Abstract Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody in dogs, and no anti-canine PD-1 therapeutic antibodies are currently available. Here, we developed two therapeutic antibodies, rat-dog chimeric and caninized anti-canine PD-1 monoclonal antibodies and evaluated in vitro functionality for these antibodies. Moreover, we conducted a pilot study to determine their safety profiles and clinical efficacy in spontaneously occurring canine cancers. In conclusion, the anti-canine PD-1 monoclonal antibody was relatively safe and effective in dogs with advanced oral malignant melanoma and other cancers. Thus, our study suggests that PD-1 blockade may be an attractive treatment option in canine cancers.Masaya IgaseYuki NemotoKazuhito ItamotoKenji TaniMunekazu NakaichiMasashi SakuraiYusuke SakaiShunsuke NoguchiMasahiro KatoToshihiro TsukuiTakuya MizunoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-16 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Masaya Igase Yuki Nemoto Kazuhito Itamoto Kenji Tani Munekazu Nakaichi Masashi Sakurai Yusuke Sakai Shunsuke Noguchi Masahiro Kato Toshihiro Tsukui Takuya Mizuno A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| description |
Abstract Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody in dogs, and no anti-canine PD-1 therapeutic antibodies are currently available. Here, we developed two therapeutic antibodies, rat-dog chimeric and caninized anti-canine PD-1 monoclonal antibodies and evaluated in vitro functionality for these antibodies. Moreover, we conducted a pilot study to determine their safety profiles and clinical efficacy in spontaneously occurring canine cancers. In conclusion, the anti-canine PD-1 monoclonal antibody was relatively safe and effective in dogs with advanced oral malignant melanoma and other cancers. Thus, our study suggests that PD-1 blockade may be an attractive treatment option in canine cancers. |
| format |
article |
| author |
Masaya Igase Yuki Nemoto Kazuhito Itamoto Kenji Tani Munekazu Nakaichi Masashi Sakurai Yusuke Sakai Shunsuke Noguchi Masahiro Kato Toshihiro Tsukui Takuya Mizuno |
| author_facet |
Masaya Igase Yuki Nemoto Kazuhito Itamoto Kenji Tani Munekazu Nakaichi Masashi Sakurai Yusuke Sakai Shunsuke Noguchi Masahiro Kato Toshihiro Tsukui Takuya Mizuno |
| author_sort |
Masaya Igase |
| title |
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| title_short |
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| title_full |
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| title_fullStr |
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| title_full_unstemmed |
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs |
| title_sort |
pilot clinical study of the therapeutic antibody against canine pd-1 for advanced spontaneous cancers in dogs |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/7ea57068e99f4b3d9f9d8844f0926591 |
| work_keys_str_mv |
AT masayaigase apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT yukinemoto apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT kazuhitoitamoto apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT kenjitani apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT munekazunakaichi apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT masashisakurai apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT yusukesakai apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT shunsukenoguchi apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT masahirokato apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT toshihirotsukui apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT takuyamizuno apilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT masayaigase pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT yukinemoto pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT kazuhitoitamoto pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT kenjitani pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT munekazunakaichi pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT masashisakurai pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT yusukesakai pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT shunsukenoguchi pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT masahirokato pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT toshihirotsukui pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs AT takuyamizuno pilotclinicalstudyofthetherapeuticantibodyagainstcaninepd1foradvancedspontaneouscancersindogs |
| _version_ |
1718387700358184960 |